Abbott Reports Positive Data of its Blood Test Technology Detecting Traumatic Brain Injury in Patients with Negative CT Scan

 Abbott Reports Positive Data of its Blood Test Technology Detecting Traumatic Brain Injury in Patients with Negative CT Scan

Abbott Reports Positive Data of its Blood Test Technology Detecting Traumatic Brain Injury in Patients with Negative CT Scan

Shots:

  • The TRACK-TBI study evaluated its blood test technology in 450 patients admitted to the emergency department of 18 U.S. Level 1 trauma centers with suspected TBI, who has also received a negative CT scan, to determine if the brain-specific glial fibrillary acidic protein (GFAP) can be used to detect
  • In the TRACK-TBI study, Abbott’s utilized its i-STAT Alinity device, evaluating the GFAP, then reviewing MRI scans taken ~2wks. later to confirm the TBI resulted in 64% of people with high GFAP were confirmed brain injury through an MRI scan, even with negative CT scan
  • Abbott’s Alinity device is a portable blood analyzer with its blood test which is in development and is poised to be the first point-of-care blood test, providing results to doctors in 15 minutes

Click here to­ read full press release/ article | Ref: Abbott | Image: Point of Care

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post